Figures & data
Figure 1 HER2 signaling pathway (Adapted from “HER2 Signaling Pathway”, by BioRender.com (2021). Retrieved from https://app.biorender.com/biorender-templates).
![Figure 1 HER2 signaling pathway (Adapted from “HER2 Signaling Pathway”, by BioRender.com (2021). Retrieved from https://app.biorender.com/biorender-templates).](/cms/asset/cda27fb2-ef06-40d8-945d-30305d55e876/dlct_a_12171575_f0001_c.jpg)
Figure 2 Structure of Trastuzumab Deruxtecan.
![Figure 2 Structure of Trastuzumab Deruxtecan.](/cms/asset/44951209-5657-4dd3-acb0-59b400a95152/dlct_a_12171575_f0002_c.jpg)
Figure 3 Trastuzumab Deruxtecan mechanism of action (Adapted from “Antibody–Drug Conjugate Drug Release”, by BioRender.com (2021). Retrieved from https://app.biorender.com/biorender-templates).
![Figure 3 Trastuzumab Deruxtecan mechanism of action (Adapted from “Antibody–Drug Conjugate Drug Release”, by BioRender.com (2021). Retrieved from https://app.biorender.com/biorender-templates).](/cms/asset/b0aac91c-9a9d-44ae-a6a9-3d16ed0e4dd8/dlct_a_12171575_f0003_c.jpg)
Table 1 Clinical Trials of Trastuzumab Deruxtecan in Non-Small Cell Lung Cancer (NSCLC)
Table 2 Comparison of DESTINY-Lung01 Trial Results Between HER-Mutant and HER2-Overexpressing Cohorts
Table 3 ILD Incidence Rate and Grading Among DESTINY Trials
Figure 4 Schema for DESTINY-Lung02. Additional details can be found at: https://clinicaltrials.gov/ct2/show/NCT04644237.
![Figure 4 Schema for DESTINY-Lung02. Additional details can be found at: https://clinicaltrials.gov/ct2/show/NCT04644237.](/cms/asset/a57e0105-07e3-47c0-879a-025c0322e0b5/dlct_a_12171575_f0004_c.jpg)